Sonova Holding AG (SONVY) AI Stock Analysis

32 Followers

Sonova Holding AG

(Other OTC:SONVY)

Select Model

Rating:73Outperform

Price Target:$76.00▲(14.10% Upside)

Action:reiterated

Date:11/12/26

The overall score of 73 reflects a fundamentally strong company with positive business momentum. The most significant positive factors are the raised guidance and market share gains highlighted in the earnings call, supported by a solid financial foundation of high profitability and cash flow. These strengths are partially offset by a high valuation multiple and a mixed technical outlook, which suggest the positive developments may already be priced in.

Positive Factors

Sustained market-share gainsRepeated wholesale growth and 11 consecutive quarters of share gains indicate improving competitive position rather than a single launch benefit. A larger installed and channel footprint can support future fittings, upgrades, recurring accessories, and stronger negotiating leverage.

Negative Factors

Cochlear implant weakness and regulatory uncertaintyThe cochlear implant segment is currently reducing growth and earnings support, with lower systems and upgrades compounded by China VBP effects. Uncertain U.S. approval timing for Integro could prolong the weakness and delay a recovery in this business.

Sonova Holding AG (SONVY) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $19.68B
Dividend Yield: 1.74%
Average Volume (3M): 15.08K
Price to Earnings (P/E): 38.5
Beta (1Y): 0.90
Revenue Growth: 3.09%
EPS Growth: -11.75%
Country: US
Employees: 18,447
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Devices

Sonova Holding AG Business Overview & Revenue Model

Company Description

Sonova Holding AG is a prominent developer, manufacturer, and global distributor of hearing health solutions for all age groups. The company's operations are divided into two core areas: Hearing Instruments and Cochlear Implants. Its product range in...

How the Company Makes Money

Sonova makes money by selling hearing care products and services through two primary channels: (1) product sales to third-party providers and (2) direct-to-consumer sales through company-owned or affiliated retail clinics. 1) Hearing Instruments (hea...

Sonova Holding AG Earnings Call Summary

Earnings Call Date:Nov 12, 2026(Q2-2027)|% Change Since:-1.98%|Next Earnings Date:May 18, 2027

Earnings Call SentimentPositive

The call was strongly positive overall. Sonova reported broad-based sales growth, continued market share gains, significant core EBIT and cash-flow growth, improved returns, strong early product reception and higher full-year guidance. The main challenges were the 10% decline in cochlear implant sales, uncertain U.S. regulatory timing for Integro, slower U.S. and Canadian retail performance, efficiency concerns around sales and marketing spending, discontinued-operation impairment charges and expected market moderation after launch-related stocking. Management nevertheless expressed confidence in continued share gains and execution in the second half.

Positive Updates

Strong First-Half Group Performance

Group sales reached CHF 1.8 billion, increasing 7.5% in local currencies and 6.7% in Swiss francs. Organic growth contributed 7 percentage points, M&A contributed 0.5 percentage points, and foreign exchange reduced reported growth by 0.8 percentage points.

Negative Updates

Cochlear Implant Sales Declined

Cochlear implant sales declined 10% in the first half. Systems were down 3% and upgrades were down 27%, reflecting China VBP, lower system sales in the United States and significantly lower upgrade sales.

Company Guidance

Sonova now expects global hearing aid market growth of 3% to 5% during the current financial year, consolidated sales growth of 6% to 8% compared with 5% to 8% previously, and core EBIT growth of 10% to 13% compared with 7% to 10% previously; currency translation is expected to be broadly neutral for sales and core EBIT for the full year. The company expects to accelerate strategic investments in the second half by low double-digit CHF million amount, within its midterm 5% to 10% sales growth target, while cochlear implant sales are expected to show an improvement in the second half subject to the timing of regulatory approval in the United States. Sonova remains within its expected CHF 35 million to CHF 40 million for noncore costs, is on track to invest around CHF 80 million to CHF 100 million annually in bolt-on acquisitions, expects CHF 90 million annualized savings and recurring profit improvement by year 4 from CHF 50 million of operational transformation investment, and will remain within its net debt-to-EBITDA corridor of 1x to 1.5x; no share buyback is being considered in the second half.

Sonova Holding AG Financial Statement Overview

Summary

Sonova demonstrates strong profitability with a 73.7% gross margin and robust cash flow generation, converting 86% of net income into free cash flow. The balance sheet is healthy with a moderate 0.66 debt-to-equity ratio. However, recent revenue and free cash flow declines temper the score.

Income Statement

74Positive

Balance Sheet

82Very Positive

Cash Flow

78Positive

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	3.57B	3.61B	3.87B	3.63B	3.74B	3.36B
Gross Profit	2.58B	2.66B	2.78B	2.62B	2.59B	2.42B
EBITDA	928.49M	930.70M	927.00M	921.70M	978.70M	960.90M
Net Income	427.14M	430.60M	540.50M	601.00M	647.50M	649.00M
Balance Sheet
Total Assets	5.63B	5.63B	5.92B	5.79B	5.55B	5.59B
Cash, Cash Equivalents and Short-Term Investments	722.10M	722.10M	687.10M	513.80M	414.80M	612.00M
Total Debt	1.71B	1.71B	1.76B	1.79B	1.81B	1.48B
Total Liabilities	2.99B	2.99B	3.24B	3.30B	3.32B	3.16B
Stockholders Equity	2.61B	2.61B	2.66B	2.47B	2.21B	2.41B
Cash Flow
Free Cash Flow	608.73M	626.10M	656.10M	624.70M	609.10M	815.90M
Operating Cash Flow	690.89M	707.50M	793.70M	753.30M	763.40M	922.50M
Investing Cash Flow	-197.38M	-192.20M	-212.70M	-234.00M	-429.50M	-707.00M
Financing Cash Flow	-428.51M	-452.90M	-401.80M	-415.30M	-523.50M	-1.37B

Sonova Holding AG Technical Analysis

Technical Analysis SentimentPositive

Last Price66.61

Price Trends

50DMA63.06Positive

100DMA58.79Positive

200DMA53.42Positive

Market Momentum

MACD1.44Positive

RSI48.76Neutral

STOCH0.56Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SONVY, the sentiment is Positive. The current price of 66.61 is below the 20-day moving average (MA) of 68.58, above the 50-day MA of 63.06, and above the 200-day MA of 53.42, indicating a neutral trend. The MACD of 1.44 indicates Positive momentum. The RSI at 48.76 is Neutral, neither overbought nor oversold. The STOCH value of 0.56 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SONVY.

Sonova Holding AG Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

SONVY against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MDT	81Outperform	$129.98B	24.77	10.60%	2.83%	9.77%	12.28%
LIVN	77Outperform	$5.01B	25.12	15.35%	―	11.71%	―
SONVY	73Outperform	$19.48B	38.45	17.08%	1.74%	3.09%	-11.75%
INSP	71Outperform	$1.80B	17.45	12.49%	―	-0.19%	131.98%
ABT	67Neutral	$189.28B	39.70	9.11%	2.35%	10.00%	-66.06%
COCH	53Neutral	$53.79M	-1.84	-9999.00%	―	11.06%	64.70%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

SONVY and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SONVY	Sonova Holding Ag Unsponsored Adr	66.61	17.14	34.64%
ABT	Abbott Laboratories	107.25	-19.63	-15.47%
MDT	Medtronic	100.99	7.80	8.37%
LIVN	LivaNova PLC	90.20	36.56	68.16%
INSP	Inspire Medical	60.54	-24.33	-28.67%
COCH	Envoy Medical, Inc. Class A	6.81	0.29	4.43%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 12, 2026

Sonova Holding AG AI Stock Analysis